Alcobra Ltd. (NASDAQ:ADHD) has been assigned a $2.00 price target by research analysts at Stifel Nicolaus in a report issued on Tuesday. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 94.17% from the company’s current price.
Other equities analysts have also recently issued reports about the company. Jefferies Group reaffirmed a “buy” rating and issued a $6.00 price objective (down from $9.00) on shares of Alcobra in a research report on Monday, October 3rd. Roth Capital set a $8.00 target price on shares of Alcobra and gave the company a “buy” rating in a research note on Saturday, October 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 target price on shares of Alcobra in a research note on Thursday, September 29th. Zacks Investment Research upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Tuesday, November 1st. Finally, WBB Securities upgraded shares of Alcobra from a “sell” rating to a “hold” rating and decreased their target price for the company from $4.00 to $1.90 in a research note on Wednesday, November 2nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $4.68.
Alcobra (NASDAQ:ADHD) opened at 1.03 on Tuesday. The company’s market capitalization is $28.39 million. Alcobra has a 12-month low of $0.83 and a 12-month high of $5.75. The stock has a 50 day moving average price of $2.05 and a 200-day moving average price of $3.26.
Alcobra (NASDAQ:ADHD) last released its quarterly earnings data on Tuesday, November 15th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.02. The company earned $7.90 million during the quarter, compared to analyst estimates of $4.30 million. Equities analysts predict that Alcobra will post ($0.94) EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Baker BROS. Advisors LP acquired a new stake in shares of Alcobra during the third quarter worth about $5,771,000. Knoll Capital Management LP acquired a new stake in shares of Alcobra during the third quarter worth about $2,799,000. VHCP Management II LLC raised its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the last quarter. VHCP Management LLC raised its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the last quarter. Finally, Jefferies Group LLC acquired a new stake in shares of Alcobra during the second quarter worth about $533,000. Institutional investors and hedge funds own 63.15% of the company’s stock.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.